Objective Insulin degludec (IDeg), a new long-acting basal insulin, and FlexTouch, a new injection device, recently became available in Japan. The efficacy and usefulness of IDeg and FlexTouch, compared with insulin glargine or detemir, were assessed in patients with type 2 diabetes mellitus.
Introduction
To prevent diabetic complications, rigorous glycemic control without fluctuation in the blood glucose (BG) level or hypoglycemia is crucial. Because the capacity of endogenous insulin secretion is decreased even in type 2 diabetes (1) , basal insulin administration is important for achieving a stable and good control of daily BG for both type 1 and type 2 diabetes. Although the current long-acting insulin analogues have major advantages in their pharmacodynamic profiles over neutral protamine Hagedorn, insulin glargine, and detemir, these analogues still exhibit a subtle peak effect, and some patients need to be injected twice daily to cover the basal insulin requirements (2) . There are numerous patients with type 2 diabetes whose BG levels cannot be sufficiently controlled, even when using these basal insulin treatments, because of their unstable glucose profiles and hypoglycemia. Therefore, an improved long-acting insulin product was needed that could provide continuous, flat, and stable insulin replacement over an entire 24-h period with one daily injection. Recently, insulin degludec (IDeg), a new, long-acting basal insulin preparation, has been made commercially available. IDeg is reported to have a terminal half-life of approximately 25 hours, which is two times longer than insulin glargine, and a duration of action of more than 42 hours (2, 3) . In addition, IDeg provides a smaller peak effect compared with traditional basal insulin (4) and thus may be an ideal basal insulin to achieve the stable control of the BG levels.
As insulin devices have developed, it has become easier to initiate insulin therapy than before. It has become easier to teach diabetic patients how to use insulin injection pens; therefore, the use of these pens is widespread. Owing to continuous improvements in the injection-system technology, a prefilled injection device, FlexTouch, was newly generated by Novo Nordisk A/S (Kobenhavn, Denmark). It has been reported that more insulin-treated pen-naive patients with type 1 and type 2 diabetes mellitus preferred FlexTouch in terms of the ease of use, insulin injection, diabetes management, and overall preference (5) . In 2013, the IDeg-prefilled FlexTouch became available in Japan; however, the efficacy of IDeg or the usefulness of FlexTouch has not yet been clinically evaluated in patients with type 2 diabetes. We herein evaluate the BG levels and their fluctuations in Japanese patients with type 2 diabetes during the use of traditional basal insulin and IDeg and determine the usefulness of FlexTouch via interview forms when the previous injection device was switched to FlexTouch.
Materials and Methods

Subjects
Twenty participants with type 2 diabetes (mean age, 67.1 years; 65% men) were recruited in this open-label longitudinal study to evaluate the efficacy of IDeg compared with traditional basal insulin. At the study enrollment, the demographic data, clinical characteristics, and current diabetes treatments were recorded. The numbers of patients who had been taking sulfonylurea, metformin, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors were 1, 4, 9, and 2, respectively. During the follow-up period, no prescribed medications except for basal insulin were changed, and no restrictions were imposed on the patients' lifestyle, except that they were encouraged to adhere to an appropriate weight-control program, including proper nutrition control and regular exercise.
This study was in compliance with the Declaration of Helsinki and was approved by the Institutional Review Board of the Shimane University Faculty of Medicine. All subjects agreed to participate in the study and gave informed consent.
Study protocol
After informed consent was obtained, all subjects continued receiving insulin glargine or detemir once per day; thereafter, basal insulin was replaced by the same dose of IDeg for the same duration of treatment (2 weeks). The patients were requested to record their self-monitoring data of the fasting BG (FBG) before breakfast and the BG level just before injection of basal insulin (BG-I) for the week immediately prior to the switch to IDeg and for the second week after the switch to IDeg (Fig. 1) . The means of the BG levels and standard deviation (SD) were calculated. The patients were also asked to record their symptoms when the glucose level was <70 mg/dL or when they noticed the signs of possible hypoglycemia.
Preference for pen devices
During the IDeg treatment, the patients switched their injection device to FlexTouch; however, the insulin regimen and needles remained the same. After using FlexTouch for 2 weeks, the patients were provided a device-specific questionnaire, which has been previously published (5) . The questionnaire used assessed the subjects' preferences in terms of device convenience and ease of use in two parts. The first part was a device-specific questionnaire comprising 21 questions; the second part was a comparative device questionnaire comprising eight questions. The first part was assessed on an ordinal 5-point scale as the percentage in favor of FlexTouch, in favor of the previous device, or a similar preference for both devices. The overall preference was calculated based on the total points from the 21 questions. The responses on the second part were either in favor of FlexTouch, in favor of the previous device, or no preference for either device.
Statistical analysis
Data are expressed as the mean ± SD. The percent change of the BG level was calculated as follows: [(BG after IDegbaseline BG)/baseline BG] ×100. Changes in the BG level and SD as well as the preference of device were examined 
Results
Subjects' baseline characteristics
The baseline characteristics of the subjects are shown in Table 1 . The number of the participants was 20 (13 men and 7 women), and the mean HbA1c was 7.3%. Sixteen patients received insulin glargine and four received insulin detemir. Four patients injected basal insulin before breakfast, one injected before dinner, and 15 injected before going to bed. Twelve patients received basal and three bolus mealtime rapid-acting insulin treatments; eight received basal insulin without bolus insulin. The mean dose of the basal insulin was 12 U per day. No patient experienced hypoglycemia during the course of this study.
Chronological changes in the BG parameters
Chronological changes in the BG levels and SDs of all the subjects are shown in Table 2 . After switching from traditional basal insulin, the patients' mean BG-I and SD during IDeg treatment tended to be decreased, but the differences were not significant. The mean FBG and SD were unchanged. The mean BG-I of some of the patients decreased, while that of others was nearly the same or increased. Thus, we compared various parameters between the patients with a decreased and increased mean BG-I (Table 3 ). The dose and the ratio of basal insulin dose/body weight were marginally higher in the patients with a decreased BG-I than in those with an increased BG-I (p=0.053 and p=0.075, respectively).
The body mass index (BMI) in the patients with a decreased BG-I was significantly higher than in the patients with an increased BG-I (p=0.022). However, the other parameters did not differ. We therefore divided the patients into two groups according to the median dose of basal insulin (10 U) and evaluated the BG levels and SDs separately in each group. Although the glucose parameters remained unchanged in the patients in the lower basal insulin injection group (<10 U), the mean BG-I and SD were significantly decreased during IDeg treatment in the patients in the higher basal insulin injection group (! 10 U) (p=0.002 and p=0.031, respectively). These parameters were increased after the switch from IDeg to the previous basal insulin (Table 4) . When the subjects were divided according to the ratio of basal insulin dose/body weight rather than basal insulin dose alone, similar results were observed (data not shown). Moreover, the percent changes were also significantly decreased in the IDeg treatment period and increased after switching to the previous insulin (Fig. 2) . We then divided the subjects into two groups according to the median BMI (24.5 kg/m 2 ). In contrast, no parameters changed in the higher and lower BMI groups (Table 5 ). In addition, the baseline BMI was not correlated with the changes in BG-I or SD (p=0.209 and p=0.878, respectively).
Preference of insulin injection device
Of the 21 device-specific questions, the preference scores of five questions were higher for FlexTouch compared with the previous devices, 11 were lower, and 5 were the same (Fig. 3) . When the significance of device preference was examined using the Wilcoxon signed-rank test, the differences were not found to be significant. The overall preference also showed no difference between FlexTouch and the previous device. In the second part of the device-specific questionnaire, the preference scores of 5 questions were lower for FlexTouch than for the previous device, one was higher, and two were the same (Fig. 4) .
According to the overall preference scores (Fig. 3) , we divided the subjects into a FlexTouch preference group (n=9) and a previous device preference group (n=9) and compared the variables (Table 6 ). In the FlexTouch group, the duration of diabetes was significantly shorter than in the previous device group (p=0.034). Furthermore, the serum creatinine and mean FBG levels were significantly lower in the FlexTouch group than in the previous device group (p=0.035 and p= 0.039, respectively). Moreover, the ratio of patients treated with basal insulin without bolus insulin treatment was significantly higher in the FlexTouch group (p=0.016). However, regardless of insulin device preference, the lowering effects on the BG levels were not different between the FlexTouch and previous device groups (8.2±24.0 vs. -2.0± 17.7 mg/dL, p=0.319 for changes in FBG and -12.9±11.9 vs. 0.4±32.8 mg/dL, p=0.268 for changes in BG-I, respectively). 
Discussion
In this study, neither parameter was significantly changed after switching to IDeg when the glucose levels and SDs were examined in all the subjects. These findings suggest that switching from traditional basal insulin to IDeg may not be useful for all patients with type 2 diabetes. However, BG-I and SD were significantly decreased during IDeg treatment in the patients receiving a higher dose (more than 10 U) of basal insulin. Moreover, these parameters increased to their baseline levels after switching to the previous basal insulin. These findings suggest that switching from basal insulin to IDeg was beneficial in the patients receiving treatment with a high dose of basal insulin.
We speculated that IDeg treatment decreased BG-I compared with the treatment with traditional basal insulin because IDeg is an ultra-long-acting basal insulin (4). However, BG-I remained unchanged when the subjects were restricted to the use of less than 10 U of basal insulin. One possibility may be that residual insulin secretion remained in the patients receiving a lower dose of basal insulin compared with the higher dose users. Therefore, BG-I was not increased in these patients even though the effect of traditional basal insulin gradually decreased until the time of the basal insulin injection. In contrast, the patients whose residual insulin secretion was already reduced needed a high dose of basal insulin; thus, IDeg was more effective for those patients. It has been previously reported that IDeg more effectively reduced the glucose levels and increased the hypoglycemia events than insulin glargine in the patients with type 1 diabetes when insulin glargine was switched to the same dose of IDeg (6) . However, the parameters of residual insulin secretion were not examined in this previous study. Another possibility is that the evaluation period was too short to examine the effect of low-dose IDeg on the BG levels. The initial day of blood monitoring was after using IDeg for 1 week. Several days are generally needed for a stable glucose-lowering effect of IDeg. Further longitudinal studies are thus necessary to investigate the relationship be- Figure 3 . The subjects' comparison assessments via a device-specific questionnaire on FlexTouch and the previously used device. The black bars indicate the number of subjects rating FlexTouch with the higher score; gray bars indicate the number of subjects rating the other device with the higher score; and white bars indicate the number of subjects who gave both the devices the same rating. 
Pen Preparation before injection
Ease of reading dose scale Q1
Ease of hearing clicks while setting dose Q2
Ease of feeling clicks while setting dose Q3
Ease of turning dose selector Q4
Confidence of setting correct dose Q5
Ease of attaching needle Q6
Confidence correctly performing air shot Q7
Speed of preparing pen for injection Q8
Insulin injection with Pen
Ease of pushing injection button Q9
Ease of holding pen stable during injection Q10
Ease of determining if full dose is injected Q11
Ease of injecting in different places on body Q12
Painlessness of self-injection Q13
Fit in hand during injection Q14
General opinion about the Pen
Confidence in injecting correct amount of insulin Q15
Usefulness of color coding to indicate insulin type Q16
Comfort in managing daily injections Q17
Comfort in controlling blood glucose levels Q18
Pen is discreet to use in public Q19
Convenience of pen size Q20
Easy to learn how to use Q21 Overall FlexTouch Previous Pen Both Preference Figure 4 . The subjects' comparison assessments via a device-specific comparative preference questionnaire on FlexTouch and the previously used device. The black bars indicate the number of subjects rating FlexTouch with the higher score; gray bars indicate the number of subjects rating the other device with the higher score; and white bars indicate the number of subjects who gave a similar rating for both devices.
FlexTouch Previous Pen Both Preference
Easier to prepare before injection Q1
Easier to injection dose Q2
Easier to depress button for injection Q3
More suitable length when injecting maximum dose Q4
Simpler to use Q5
Easier to use Q6
Trust more to accurately deliver insulin Q7
Safer to operate Q8 
Number of subjects been previously reported that the events of nocturnal hypoglycemia were significantly reduced in the patients treated with IDeg compared with those treated with insulin glargine (8) . The glucose-lowering effects of insulin glargine and detemir last a maximum of approximately 4 and 7 hours, respectively, after injection and then decrease gradually (9). The peak effects of glargine and detemir may cause nocturnal hypoglycemia. In contrast, the glucose-lowering effects of IDeg are reported to be flat and stable over 24 hours when measured by the euglycemic glucose clamp method (4). Therefore, switching from conventional basal insulin to IDeg may be beneficial even if the FBG and HbA1c levels do not change. Because no hypoglycemic events were reported in the present short-term study of relatively poorly controlled patients, further studies are needed to examine this point in the future. The stability effect of IDeg is clinically useful for controlling daily BG levels. If a patient's BG levels are constantly fluctuating, it is difficult to change the insulin administration dose. In contrast, adjusting the insulin dose becomes easier if the BG levels are stabilized. Previous studies have shown that the BG fluctuation improved after replacing insulin glargine with IDeg (10). As described previously, the stability of IDeg's action leads to a stable BG. In the present study, the SD value of BG-I was significantly decreased after switching from basal insulin to IDeg in the patients treated with a higher dose; thereafter, it returned to the baseline level. Therefore, these findings confirm the stable glucose-lowering effect of IDeg in the patients with type 2 diabetes.
Previous studies demonstrated that FlexTouch accurately and consistently delivered insulin (11) . Moreover, FlexTouch is currently the only prefilled pen that has a push button that does not extend at any dose (as opposed to the traditional prefilled pens which require more thumb or finger pressure for injection). This may make it easier for patients to inject insulin. In the present study, we evaluated the preference for FlexTouch when the insulin device was exchanged for 2 weeks. Half of the patients preferred FlexTouch compared with the previous device they used and half did not. In addition, the patients with a shorter duration of diabetes, single insulin injection, and lower FBG levels tended to prefer FlexTouch compared with their previous insulin device. In other words, the patients with a longer duration of diabetes receiving basal and three bolus mealtime rapid-acting insulin treatments may have become more accustomed to the insulin device they were using. However, the insulin device preference made no difference in the glucose-lowering effect of IDeg.
There are some limitations associated with the present study. First, the sample size was not large enough to make definite conclusions. A large-scale study ought to be conducted to confirm the present findings. However, we chronologically evaluated the BG levels and SDs after switching from IDeg to the previous insulin and found that the parameters evaluated returned to the baseline levels. These findings support the effectiveness of IDeg. Second, we analyzed only subjects who accepted the study protocol; therefore, we are not able to exclude potential selection bias. Third, due to the limited number of subjects, we could not separately assess insulin glargine and detemir. Fourth, the BMIs in the present populations were lower than those observed in Western populations, and the capacity of insulin secretion and degree of obesity in Asian populations are known to differ from Western populations (12) . Thus, largescale longitudinal studies should be performed in other countries. In contrast, previous studies showed no differences in the BG levels between IDeg and glargine (7, 8) .
We found that the BG-lowering effects of high-dose IDeg may be more favorable than traditional basal insulin. The contradictory results between the previous studies and the present study may be due to the differences in the study protocol, basal insulin doses, and insulin injection devices.
In conclusion, replacing basal insulin with IDeg is useful for the stable and accurate control of the BG levels in the patients with type 2 diabetes receiving higher doses of basal insulin. The patients with a short duration of diabetes receiving a single injection of insulin preferred switching from their device to FlexTouch.
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